Generate Biomedicines, Inc. was incorporated in August 2018 under Delaware law. As a clinical-stage generative biology company, it pioneered an AI-driven biotechnology platform called the Generate Platform, which combines computational models with scalable biological hardware to design and develop novel therapeutic proteins. Its most advanced candidate, GB-0895, is a computationally engineered anti-TSLP monoclonal antibody currently in a pivotal Phase 3 trial for severe asthma. The platform's capabilities have been further demonstrated by advancing two additional oncology candidates into Phase 1 trials by 2026.